Zacks: Brokerages Set $4.49 Target Price for CounterPath, Corp. (CPAH)

Shares of CounterPath, Corp. (NASDAQ:CPAH) (TSE:CCV) have received an average broker rating score of 2.00 (Buy) from the one brokers that cover the company, Zacks Investment Research reports. One investment analyst has rated the stock with a buy recommendation.

Brokers have set a one year consensus target price of $4.49 for the company and are expecting that the company will post $0.02 earnings per share for the current quarter, according to Zacks. Zacks has also given CounterPath an industry rank of 163 out of 265 based on the ratings given to related companies.

A number of equities research analysts have issued reports on the stock. ValuEngine lowered shares of CounterPath from a “sell” rating to a “strong sell” rating in a report on Sunday, December 31st. Zacks Investment Research upgraded shares of CounterPath from a “hold” rating to a “buy” rating and set a $3.00 target price on the stock in a report on Monday, December 18th.

Shares of CounterPath (NASDAQ:CPAH) opened at $6.66 on Monday. The stock has a market cap of $36.65, a P/E ratio of -13.06 and a beta of -0.73. CounterPath has a fifty-two week low of $1.75 and a fifty-two week high of $7.00.

ILLEGAL ACTIVITY NOTICE: “Zacks: Brokerages Set $4.49 Target Price for CounterPath, Corp. (CPAH)” was originally posted by American Banking News and is owned by of American Banking News. If you are accessing this piece on another domain, it was copied illegally and republished in violation of United States and international copyright and trademark laws. The legal version of this piece can be accessed at

About CounterPath

CounterPath Corporation designs, develops and sells software and services that enable enterprises and telecommunication service providers to deliver unified communications (UC) services, including voice, video, messaging and collaboration functionality, over their Internet Protocol (IP)-based networks.

Get a free copy of the Zacks research report on CounterPath (CPAH)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for CounterPath Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CounterPath and related companies with's FREE daily email newsletter.

Leave a Reply